Urine L-FABP Oxidation Analysis for CKD and AKI Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for quantifying L-type fatty acid binding protein (L-FABP) in urine samples are limited in sensitivity, particularly for oxidized forms, and do not effectively distinguish between chronic kidney disease (CKD) and acute kidney injury (AKI), leading to inaccurate diagnosis.
Innovation Solution
A method is developed to enhance the antigen-antibody reaction sensitivity for oxidized L-FABP by using chaotropic reagents or organic amine compounds, allowing for higher measurement sensitivity compared to unoxidized L-FABP, and calculating an oxidation rate based on differential sensitivity conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ELISA methods are used to measure L-FABP in urine, then the measurement can be performed, but the sensitivity is insufficient especially for oxidized L-FABP forms
Solution Approach 1:
The patent applies parameter changes by modifying the measurement conditions through pretreatment of urine samples with denaturants (urea, guanidine, SDS) and reducing agents (glutathione, cysteine, penicillamine). These chemical modifications alter the protein structure and oxidation state, enabling the antibody to recognize and bind to oxidized L-FABP forms that were previously undetected, thereby significantly improving measurement sensitivity and diagnostic accuracy.
Solution Approach 2:
The patent uses reducing agents and denaturants as intermediary substances that facilitate the antigen-antibody reaction. These intermediaries modify the L-FABP structure to expose epitopes that are recognized by the antibody, thereby mediating the detection process and enabling sensitive measurement of oxidized L-FABP that would otherwise be inaccessible to the antibody.
2Measurement precision
If antibodies binding to inner region of L-FABP are used, then specific binding is achieved, but measurement values are largely changed due to methionine oxidation
Solution Approach 1:
The patent applies preliminary action by pretreating the urine sample with reducing agents and denaturants before the antigen-antibody reaction. This preliminary treatment stabilizes the L-FABP structure against methionine oxidation and maintains the conformational epitopes that the antibody recognizes, ensuring consistent and reliable measurement values regardless of the oxidation state of L-FABP in the original sample.
Solution Approach 2:
The patent uses reducing agents (glutathione, cysteine, penicillamine) as protective agents that cushion against methionine oxidation during sample processing and storage. These agents prevent oxidative modifications that would alter the antibody binding sites, thereby maintaining measurement consistency and reliability throughout the diagnostic process.
3Reliability
If total L-FABP amount is measured to detect kidney diseases, then kidney damage can be detected, but the method cannot effectively distinguish between CKD and AKI
Solution Approach 1:
The patent applies local quality by measuring different oxidation states of L-FABP separately through differential pretreatment conditions. By using specific combinations of reducing agents and denaturants, the method can selectively detect and quantify oxidized L-FABP (indicative of chronic damage) versus total L-FABP (indicative of acute injury), thereby preserving the information needed to distinguish between CKD and AKI while maintaining reliable disease detection capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables accurate quantification of L-FABP and oxidized L-FABP, facilitating the differentiation between CKD and AKI through urine analysis, thereby improving diagnostic accuracy.
Implementation Method 1
enhance the antigen-antibody reaction sensitivity for oxidized L-FABP by using chaotropic reagents or organic amine compounds
Implementation Method 2
The structure of L-FABP is changed due to the modifications of methionine oxidation, and the inner region of L-FABP molecules is exposed
Implementation Method 3
The structure of L-FABP is changed due to the modifications of methionine oxidation, and the inner region of L-FABP molecules is exposed
Data Source
AI summary
Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.